Clinical Takeaway
In this Phase 3 randomized controlled trial of 820 adults with chronic low back pain, VER-01, a full-spectrum Cannabis sativa extract, was evaluated over a 12-week blinded treatment period with extended follow-up reaching approximately one year. The trial design includes a randomized withdrawal phase, allowing researchers to assess both sustained benefit and the consequences of discontinuation. These results will provide some of the most rigorous clinical evidence to date on cannabinoid-based treatment for one of the most prevalent pain conditions globally.
#1 Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.
Citation: Karst Matthias et al.. Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.. Nature medicine. 2025. PMID: 41023483.
Design: 5 Journal: 4 N: 2 Recency: 2 Pop: 2 Human: 1 Risk: -2
This phase 3 trial addresses a critical clinical gap by evaluating a standardized cannabis extract as an alternative to opioids and NSAIDs for chronic low back pain, a condition affecting over 500 million people globally with currently inadequate pharmacologic options. The rigorous double-blind, placebo-controlled design with 820 participants provides the robust evidence needed to establish whether full-spectrum cannabis can offer meaningful efficacy and safety advantages for one of the most prevalent causes of disability and healthcare burden worldwide. If successful, this study could support regulatory approval and clinical integration of a potentially safer analgesic option for the millions of patients with CLBP who experience inadequate pain relief or intolerable adverse effects from conventional
Quality Gate Alerts:
- Preclinical only
Methodological Considerations:
- Open-label design — placebo effect not excluded
Abstract: Chronic low back pain (CLBP) affects over half a billion people worldwide. Current pharmacologic treatments offer limited efficacy and carry substantial risks, warranting the development of safe and effective alternatives. This multicenter, randomized, placebo-controlled phase 3 trial evaluated the efficacy and safety of VER-01 in CLBP. It enrolled 820 adults with CLBP (VER-01, n = 394; placebo, n = 426) and included a double-blind 12-week treatment phase (phase A), a 6-month open-label extension (phase B), followed by either a 6-month continuation (phase C) or randomized withdrawal (phase D). The primary endpoint of phase A was a change in mean numeric rating scale (NRS) pain intensity, with a change in total neuropathic pain symptom inventory (NPSI) score as a key secondary endpoint in participants with a neuropathic pain component (PainDETECT > 18). The primary endpoint for phase D was time to treatment failure. The study met its primary endpoint in phase A, with a mean pain reduction of -1.9 NRS points in the VER-01 group (mean difference (MD) versus placebo = -0.6, 95% confidence interval (CI) = -0.9 to -0.3; P < 0.001). Pain further decreased to -2.9 NRS points in phase B, with effects sustained through phase C. The study also met its key secondary endpoint of phase A, with a mean NPSI decrease of -14.4 (standard error, 3.3) points from baseline in the VER-01 arm (MD versus placebo = -7.3, 95% CI = -13.2 to -1.3; P = 0.017). Although phase D did not meet its primary endpoint (hazard ratio = 0.75, 95% CI = 0.44-1.27; P = 0.288), pain increased significantly more with placebo upon withdrawal (MD = 0.5, 95% CI = 0.0-1.0; P = 0.034). In phase A, the incidence of adverse events-mostly mild to moderate and transient-was higher with VER-01 than with placebo (83.3% versus 67.3%; P < 0.001). VER-01 was well-tolerated, with no signs of dependence or withdrawal. VER-01 shows potential as a new, safe and effective treatment for CLBP. ClinicalTrials.gov registration: NCT04
🔙 This phase 3 trial adds meaningful data to the cannabis-for-pain literature by demonstrating efficacy of a full-spectrum extract in a large, well-controlled CLBP population, addressing a genuine clinical need given the limitations and risks of conventional analgesics. However, several factors warrant careful interpretation: the study design does not isolate which cannabinoid or terpene profiles drive benefit, baseline pain severity and functional impairment metrics are not detailed in the abstract, and long-term safety data beyond six months remains unclear for a condition patients often manage chronically. The lack of head-to-head comparison with standard-of-care options like physical therapy, NSAIDs, or other analgesics limits our ability to position this therapy within existing treatment hierarchies. For clinicians considering cannabis as an adjunctive or alternative option in select CLBP patients who have failed or cannot tolerate conventional approaches, this trial provides reassurance regarding efficacy and safety in a rigorous setting, though individual patient screening for contra